This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We thank Dr Flais and Drs MacLean and Hannaway for their comments. We stand corrected regarding the statement about previous literature reports of angioedema recurring in patients switched from ACE inhibitor to ARB therapy. However, some of these are reports of angioedema occurring with ARB therapy without such prior problem with ACE inhibition—indeed, this was the case in the first report with losartan use.¹ Angioedema is a rare allergic reaction that existed before ACE inhibitors and ARBs were invented and will occur in response to other allergens as well. The increased incidence of this reaction with ACE inhibition and even more with the use of vasopeptidase inhibitors² has focused attention on the role of bradykinin and, specifically, the heightened probability of an amplified allergic reaction when the enzymatic degradation of bradykinin is impaired.³ This mechanism should not be relevant to an ARB-related allergic reaction, and therefore ARBs would . . . [Full Text of this Article]